MAPT and Alzheimer disease: We quantitatively measured the levels of Aβ1–40, Aβ1–42, and Tau, the markers of AD according to the amyloid cascade and Tau hypothesis, and CHI3L1 in the serum of AD patients and healthy controls by ELISA.